Podcast 32: Blockbuster Muscle: Small Molecules or Biologics?

 

 

September 1, 2021

Which modality, small molecules or biologics, leads among the top-selling products? A look at the top-selling products industry-wide and blockbusters from select leading bio/pharma companies provides the answer. For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers)

  • Modality of top-selling products
  • New drug approvals: small molecules versus biologics
  • Potential blockbusters: small molecules and biologics
  • Biogen’s and Eisai’s aducanumab
  • Argenx’s efgartigimod
  • Bristol-Myers Squibb’s mavacamten
  • UCB’s bimekizumab
  • Bristol Myers Squibb’s/bluebird bio’s idecabtagene vicleucel (ide-cel)
  • Ascendis Pharma’s TransCon hGH (lonapegsomatropin)

Sponsor: LGM Pharma